

Curriculum Vitae

DONALD R. WESTERHAUSEN, JR., M.D.

Home Address and Phone: 52346 Spring Arbor Court
Granger, IN 46530
(574) 273-5222

Work Address Beacon Medical Group
Advanced Cardiovascular Specialists Riverpointe
500 Arcade Ave., Suite 400
Elkhart, IN 46514
Interventional Cardiologist

Affiliations: Midwest Cardiovascular Research and Education Foundation, Board President
500 Arcade Ave., Suite 400
Elkhart, IN 56514
574-522-0337

Hospital Affiliations Elkhart General Hospital
600 East Boulevard
Elkhart, IN 46514

Saint Joseph Regional Medical Center
5215 Holy Cross Parkway
Mishawaka, IN 46545

Goshen General Hospital
200 High Park Avenue
Goshen, IN 46526

Memorial Hospital of South Bend
615 N. Michigan Street
South Bend, IN 46601

Kindred Hospital
215 W. 4th Street, Suite 200
Mishawaka, IN 46544

Place of Birth: Harvey, Illinois

EDUCATION:

College Northwestern University
Evanston, Illinois
B.S. (Education), 1981
Magna Cum Laude

Medical University of Minnesota Medical School
Minneapolis, Minnesota
M.D., 1985

PROFESSIONAL EXPERIENCE:

2011-Present Interventional and Consultative Cardiologist
Beacon Medical Group
Advanced Cardiovascular Specialist - RiverPointe
500 Arcade Ave, Suite 400
Elkhart, Indiana 46514

2005-Present Medical Director
Cardiac Catheterization Laboratory
Elkhart General Healthcare System
Elkhart, Indiana

2004-Present Board Member and Current President
Midwest Cardiovascular Research and Education Foundation
Elkhart, Indiana

1998-2003 Medical Director
Cardiac Catheterization Laboratory
Saint Joseph Regional Medical Center
South Bend, Indiana

1993-2011 Interventional and Consultative Cardiologist, Partner & President (intervals)
Midwest Medical Group, LLC.
South Bend, Indiana

1992-1993 Interventional/Advanced Angioplasty Fellow
The Mid-America Heart Institute
Saint Luke's Hospital
Kansas City, Missouri
(Preceptors: Drs. Geoffrey O. Hartzler, Barry D. Rutherford, Thomas M Shimshak, Lee V. Giorgi and Wamer Johnson)

1990-1992 Clinical Fellow
Department of Medicine, Cardiovascular Division
Washington University School of Medicine
St. Louis, Missouri

1988-1990 NIH Postdoctoral Research Fellow
Department of Medicine, Cardiovascular Division
Washington University School of Medicine
St. Louis, Missouri
(Preceptors, Dr. Joseph Billadello and Dr. Burton E. Sobel)

1985-1988 Intern and Resident in Internal Medicine
Parkland Hospital
University of Texas Health Science Center
Dallas, Texas

HONORS AND SOCIETIES:

Mortarboard Honor Society, Northwestern University, 1981
Alpha Omega Alpha, University of Minnesota Medical School, 1985
John S. Miller Award for Outstanding Resident, Parkland Memorial Hospital, 1988

AWARDS:

American Heart Association - Missouri Affiliate Fellowship, 1989
American Federation for Clinical Research - Outstanding Trainee Award, 1990

CERTIFICATION:

Diplomat, Subspecialty Board of Internal Medicine-Interventional Cardiology, 1999
Diplomat, Subspecialty Board of Internal Medicine-Cardiovascular Disease, 1991, Recertified 2002
Diplomat, American Board of Internal Medicine, 1988

RESEARCH ACTIVITIES:

CLEAR: A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease who are Statin Intolerant, ESPERION, 2017-on-going, Site Sub-investigator

PRIME: Pre-discharge Initiation of Ivabradine in the Management of Heart Failure, DUKE, 2016-on-going, Site Sub-investigator

RE-CIRCUIT: Randomised Evaluation of dabigatran etexilate Compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy. Boehringer-Ingelheim, Site Sub-investigator, 2015-ongoing

AGEIS 1: CSLCT-HDL-12-77: A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Myocardial Infarction. CSL Behring LLC, Site Sub-investigator, 2015-2016

RE-DUAL PCI: A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAf) that have undergone a percutaneous coronary intervention (PCI) with stenting. Boehringer-Ingelheim, Site Primary Investigator, 2015-ongoing

ODYSSEY: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome. Sanofi-Aventis, Site Primary Investigator, 2014-ongoing

STRENGTH: A Long Term Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova in High Cardiovascular Risk Patients with Hypertriglyceridemia. Astra Zeneca, Site Sub-investigator, 2014-ongoing

REGULATE: A Randomized, Open-Label, Multicenter, Active-Controlled, Parallel Group Study to Determine the Efficacy and Safety of the Reg1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention. Regado Biosciences, Site Primary Investigator, 2014-2014

THEMIS: A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90mg Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction, or Stroke in Patients with Type 2 Diabetes Mellitus. Astra Zeneca, Site Sub-investigator, 2014-ongoing

AVOID-HF: Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure. Gambro, Site Primary Investigator, 2013-2014

TAK-850: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes Of TAK-875, 40 mg in Addition to Standard of Care in Subject With Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events. Takeda, Site Sub-investigator, 2013-2014

ABSORB: A randomized controlled trial to evaluation the Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions. Abbott Vascular, Site Primary Investigator, 2013-ongoing

ACCELERATE Study: Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Rick for Vascular Outcomes. Cleveland Clinic, Covance & Lilly, Site Sub-investigator, 2012-2015

EUCLID: A randomised, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease. DUKE & AstraZeneca, Site Sub-investigator, 2012-2016

SAFE PCI: Study of Access Site for Enhancement of PCI for Women (DUKE) Site Primary Investigator, 2012-2013

TRANSLATE-ACS: Treatment with ADP receptor inhibitor: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (Translate-SCS) Registry. Duke and Lilly, Site Primary Investigator, 2012-2013

DAL-OUTCOMES II: A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD). Roche and Duke, Site Sub-investigator, 2012-2012

DAL PLAQUE II: Phase IIIB, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Effect of Treatment with Dalcetrapib 600mg on Atherosclerotic Disease as Measured by 1. Coronary Intravascular Ultrasound (IVUS), Quantitative Coronary Angiography II, Carotid B-Mode Ultrasound Intima Medial Thickness (IMT) and Total Plaque Volume in Subjects Undergoing Coronary Angiography who have Coronary Artery Disease (CAD). Roche and Montreal Heart, Site Primary Investigator, 2011-2012

ALECARDIO ROCHE: Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome (ACS) Event and Type 2 DM. Cleveland Clinic, Site Sub-Investigator, 2011-2013

PEGASUS TIMI 54: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multinational Trial to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of MI. Astra Zeneca, Site Primary Investigator, 2011-2015

ODYSSEUS: A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID on Cardiac Geometry and Function in Patients with Atrial Fibrillation and Left Atrial Enlargement. Sanofi-Aventis, Site Sub-Investigator, 2011-2012

TRILOGY: A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST Elevation MY who are Medically Managed. Eli-Lilly, Site Sub-Investigator, 2011-2012

DAL-OUTCOMES: A Phase III, Double-Blind, Randomized Placebo-Controlled Study, to Evaluate the Effects of RO4607381 on Cardiovascular (CV) Risk in Stable CHD Patients, with a Documented Recent Acute Coronary Syndrome (ACS). ROCHE and Cleveland Clinic, Site Sub-Investigator, 2010-2012

DAPT: A Prospective, Multi-Center, Randomized, Double-Blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention (PCI) with either Drug-eluting Stent (DES) or Bare Metal Stent (BMS) Placement for the Treatment of Coronary Artery Lesions. Harvard, Site Primary Investigator, 2010-2014

AQUARIUS: A 104 week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients with Coronary Artery Disease when Added to Optimal Background Therapy. Site Primary Investigator, 2009-2013.

XIENCE V USA: Xience V Everolimus USA Post Approval Study, Site Primary Investigator, 2008-2013

SATURN: A 104 week, Randomized, Double-Blind, Multicenter Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Patients with Coronary Artery Disease, Site Primary Investigator, 2008-2011

TRACER: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome. Schering-Plough, Site Primary Investigator, 2008-2011

CHAMPION: A clinical trial comparing Cangrelor to Clopidogrel in subjects who require percutaneous coronary intervention. The Medicine Co, Site Primary Investigator, 2007-2010

ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg BID for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial Fibrillation/Atrial Flutter (AF/AFL) (ATHENA). Sanofi-Aventis, Site Sub-Investigator, 2006-2008

Vulnerable Plaque Intervention Peer Leader. 2005

STRADIVARIUS: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimobant 20mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSound), in Overweight Patients with Clustering Risk Factors. Sanofi-Aventis, Site Principal Investigator, 2005-2007

ACUTY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Lovenox/Clexane (Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation. Medicine Co., Site Principal Investigator, 2004-2007

D.E.S.cover (Drug Eluting Stent) Registry Protocol. Sponsored by Cordis, Site Sub-Investigator, 2005-2006.

ILLUSTRATE: Phase 3 Multi-centered, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529, 414/Atorvastatin, Administered Orally, Once Angiographically Documented Coronary Heart Disease. Pfizer, Site Principal Investigator, 2004-2006

The PAMI-No SOS (No Surgery on Site) Site Sub-Investigator. Published *Amer Coll Cardiol* 2004; 39:1943-1950

Air-PAMI: A Randomized Trial of Thrombolysis Compared to Transfer for Acute Intervention in High-Risk MI Patients. Site Principal Investigator, 1996-1998. Published *J Am Coll Cardiol* 2002;11-1713, 2002

A Randomized, Parallel - Group Comparison of The ACS MULTI-LINK™ Coronary Stent System versus the Palmaz-Schatz^R Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions, Site Principal Investigator, 1995-1997

Guidance by Ultrasound Imaging for Decision Endpoints Trial Phase II (GUIDE II), Site Co-Investigator, 1994-1995

Primary Angioplasty in Myocardial Infarction - 2 Trial (PAMI II), Site Principal Investigator, 1994-1995

PUBLICATIONS:

1. Hopkins WE, Westerhausen DR, Sobel BE, and Billadello JJ: Transcriptional and post-transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor. *Nuc. Acid. Res.* 19:163-168, 1991.
2. Westerhausen DR, Hopkins WE, and Billadello JJ: Multiple transforming growth factor-B inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. *J. Biol. Chem.* 266:1092-1100, 1991.
3. Hopkins WE, Westerhausen DR, Fujii S, Billadello JJ, and Sobel BE: Augmentation of expression of plasminogen activator inhibitor type-1 in Hep G2 cells by specific factors released from platelets. *Thrombo. Hemosta.* 66(2):239-245, 1991.
4. Westerhausen,DR, and O'Keefe J: Is direct PTCA superior to thrombolysis in treating AMI's? *IM* 14:48-58, 1993.
5. Sandler MA, Zhang J, Westerhausen DR, and Billadello JJ: A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene. *J. Biol. Chem.* 269:21500-21504, 1994.
6. Davila-Roman VG, Westerhausen DR, Hopkins WE, Sicard GA, and Barzilai B: Transesophageal echocardiography in the detection of cardiovascular sources of peripheral vascular embolism. *Annals of Vascular Surgery* 9:252-260, 1995.
7. Grines CL, Westerhausen DR, Grines LL, Hanlon JT, Logemann, TL, Niemela M, Weaver WD, Graham, M., Boura J, O'Neill WW, and Balestrini C. Air PAMI Study Group: A randomized trial of transfer for primary Angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: The Air Primary Angioplasty in Myocardial Infarction Study. *J. Am. Coll. Cardiol.* 39:11-1713, 2002.
8. Lopez, J. J., Arain, S. A., Madder, R., Parekh, N., Shroff, A. R. and Westerhausen, D. (2014), Techniques and best practices for optical tomography. *Cathet. Cardiovasc. Intervent.*, 84: 687-699, 2014.

ABSTRACTS:

1. Westerhausen DR, Hopkins WE, Sobel BE, and Billadello JJ: Transcriptional regulation of type-1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. *J. Cell. Biochem.* (suppl. 13E):P320, 1989.
2. Hopkins WE, Westerhausen DR, Billadello JJ, and Sobel BE: Induction of increased expression of type-1 plasminogen activator inhibitor mRNA by platelet products. *Circulation* 80:II-463, 1989.
3. Westerhausen DR, Hopkins WE, Sobel BE, and Billadello JJ: A transforming growth factor-beta(TGF-B) inducible enhancer regulates expression of the plasminogen activator inhibitor type-1(PAI-1) gene in Hep G2 cells. *Clin. Res.* 38:286A, 1990.
4. Westerhausen DR, Hopkins WE, and Billadello JJ: Two transforming growth factors beta inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. *Circulation* 82:III-51, 1990.
5. Hopkins WE, Westerhausen DR, Billadello JJ, and Sobel BE: Augmented genetic expression of PAI in Hep G2 cells by specific growth factors in platelets. *Circulation* 82:III-502, 1990.
6. Westerhausen DR, O'Keefe J, Rutherford BD, Giorgi LV, Shimshak TM, and Hartzler GO: Lack of an independent effect of gender on short and long-term mortality in patients treated with direct angioplasty for acute MI. *J. Am. Coll. Cardiol.* 21:175A, 1993.
7. Westerhausen DR, Rutherford BD, Hartzler GO, and O'Keefe J: Long-term results of a 12 year experience with infarct angioplasty: Complete revascularization prior to dismissal improves late survival. *J. Am. Coll. Cardiol.* 21:43A, 1993.
8. Bailey WL, Westerhausen DR, Rutherford BD, McConahay DR, Johnson W, Giorgi LV, Shimshak TM, Ligon RW, and Hartzler GO: Long term outcome after angioplasty in the setting of rest angina pectoris. *J. Am. Coll. Cardiol.* 21:452A, 1993.
9. Bailey WL, Westerhausen DR, Rutherford BD, McConahay DR, Johnson W, Giorgi LV, Shimshak TM, Ligon RW, and Hartzler GO: Characteristics and outcomes of diabetic patients presenting for coronary angioplasty. *J. Am. Coll. Cardiol.* 21: 273A, 1993.
10. Westerhausen DR, Bailey WL, Hartzler GO, McConahay DR, Johnson WL, Giorgi LV, Shimshak TM, Ligon RW, and Rutherford BD: Determinants of procedural outcome with PTCA in the 1990's. *Circulation* 88:I-217, 1993.
11. Smucker ML, Kil D, Howard PF, Wefald FC, Sarnat WS, and Westerhausen DR: Intracoronary ultrasound guidance in coronary atherectomy: implications for new technology. *Circulation* 88:I-597,1993.